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pulmonary artery distensibility and has been shown to correlate with vasoreactivity studies in patients
with idiopathic pulmonary arterial hypertension. We have previously noted a relationship between
invasive hemodynamic vasoreactivity testing and long-term response to sildenafil in patients with
inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We therefore set out to deter-
mine whether RAC can provide useful correlatory non-invasive data.
METHODS: Patients recruited to a randomized, controlled trial (RCT) of sildenafil at 40 mg 3 times daily
underwent additional magnetic resonance imaging (MRI) at the baseline of the trial. Eighteen patients had
an MRI that led to a diagnosis of inoperable distal CTEPH or significant residual CTEPH post-operatively.
The primary end-point was improvement in 6-minute walk test (6MWT) with secondary end-points of right
heart catheterization–based hemodynamics, N-terminal pro–brain natriuretic peptide (NT pro-BNP) and
functional class. RAC assessed by MRI was correlated with trial end-points.
RESULTS: Fourteen subjects with baseline MRI completed the protocol. RAC was the only baseline
variable that correlated at 1 year to the primary end-point of improvement in 6MWT (r  0.7, p 
0.006), and also to a change in NT pro-BNP (r  0.59, p  0.03). Using a cut-off of RAC over 20%
there was an 87.5% sensitivity (95% confidence interval [CI]: 45% to 100%) and a 66.7% specificity
(95% CI: 22% to 96%) for an improvement in 6MWT of 40 meters.
CONCLUSIONS: RAC correlates with functional response to sildenafil, as measured by the 6MWT, and
improved heart function, as measured by NT pro-BNP. RAC shows potential in understanding and
possibly predicting treatment response.
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aChronic thromboembolic pulmonary hypertension (CTEPH)
s considered to represent a rare consequence of acute pul-
onary embolic disease.1 After an acute event, thrombus
ails to adequately resolve and organizes, resulting in chronic
Reprint requests: Joanna Pepke-Zaba, MD, Pulmonary Vascular Dis-
ases Unit, Papworth Hospital, Papworth Everard, Cambridgeshire CB23
RE, UK. Telephone: 44-14-80-830541. Fax: 44-14-80-364998.oE-mail address: joanna.pepke-zaba@papworth.nhs.uk
053-2498/$ -see front matter © 2010 International Society for Heart and Lung
oi:10.1016/j.healun.2009.12.014bstruction of the pulmonary vasculature. If untreated, this
auses progressively worsening pulmonary hypertension,
ight ventricular dysfunction and death.2 Patients are rou-
inely treated with anti-coagulation and supportive therapy,
ut until recently the only proven treatment option effec-
ively targeting pulmonary hypertension has been pulmo-
ary endarterectomy (PEA). If a patient has surgically in-
ccessible disease or significant post-operative disease,
ptions are limited. Recently, we reported the results of a
Transplantation. All rights reserved.
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611Toshner et al. MRI in CTEPHandomized, controlled trial (RCT) showing that targeting
ascular remodeling in CTEPH with sildenafil may be ben-
ficial.3 Evidence is also accumulating from a multicenter
CT of bosentan4 and open-label trials of sildenafil, pro-
tanoids and bosentan.5–9 As these trials have not shown a
arge, clear-cut response in all subjects, it is apparent that
e need better tools to understand who responds and why.
Within our cohort of patients involved in the RCT of
ildenafil there was a significant degree of vasoreactivity on
ormal vasodilator challenge studies with inhaled nitric ox-
de and intravenous sildenafil at baseline,10 which modestly
orrelated with improvement in pulmonary vascular resis-
ance (PVR) at 1 year.3 Previously it was hypothesized that
his vasoreactivity reflects similarities to idiopathic pulmo-
ary arterial hypertension (PAH) in distal pulmonary artery
emodeling and histopathologic characteristics in small ves-
els.11 This focus on the similarities of the distal vasculature
verlooks the importance of the proximal vasculature, par-
icularly its response to downstream remodeling and cou-
ling to the right ventricle. In normal physiology the ma-
ority of vasoreactivity is in the resistance vessels in the
istal vascular bed; however, it is well established that,
nder conditions of vascular dysfunction, there are also
lterations in the vasoactive ability of proximal arteries.12,13
Relative area change (RAC) of the proximal pulmonary
rtery is a measurement of pulmonary artery distensibility and
as been shown to correlate well with vasoreactivity studies in
atients with idiopathic pulmonary arterial hypertension
IPAH).14 It measures the change in relative area between
ystole and diastole in the pulmonary arteries using MRI or
chocardiography.14–16 PA distensibility is of clear importance
n disease progression with a higher distensibility index, and
herefore preserved compliance predicting survival in a cohort
f patients with IPAH and associated causes of PAH.16 We
herefore hypothesized that PA distensibility could provide
on-invasive data useful in the follow-up of distal CTEPH. We
resent data showing a significant relationship between RAC
nd functional response to long-term sildenafil treatment in
istal CTEPH. This adds further evidence showing that mea-
urement of PA distensibility is a potentially useful marker of
isease progression.
ethods
atients
he local ethics review committee approved this study. Full
ritten, informed consent was obtained from all subjects. Sub-
ects were diagnosed with CTEPH according to standard clas-
ification.17,18 The methods and patients were described in
etail previously.3 The diagnosis was made by a multidisci-
linary team of PEA surgeons, physicians and radiologists
sing at least 2 of the following 4 imaging modalities; venti-
ation/perfusion scanning; conventional pulmonary angiogra-
hy; computed tomography (CT) pulmonary angiography; and
agnetic resonance imaging (MRI) pulmonary angiography.
ubjects were enrolled with either a de novo diagnosis of distal tnoperable disease or post-PEA residual distal disease and
ignificant residual pulmonary hypertension, and were required
o be clinically stable on unchanged therapy, including stable
nti-coagulation for a period of 3 months. Subjects were ex-
luded if there was any co-existing significant disease, in par-
icular pulmonary or cardiac disease, including obstructive
irway disease, pulmonary fibrosis, congenital heart disease
nd valvular heart disease. Patients were also excluded of they
ad any pathology that could interfere with the undertaking
nd interpreting of a 6-minute walk test (6MWT).
Eighteen subjects entered into a randomized, controlled trial
f sildenafil for the treatment of distal CTEPH underwent MRI
can at baseline entry into the trial. Subjects were then ran-
omized to sildenafil titrated up to 40 mg 3 times daily or
lacebo for 3 months. At the end of the placebo-controlled
hase, the subjects were then enrolled in an open-label phase
or a further 9 months (Figure 1). The primary trial end-point
as the 6MWT and secondary end-points were hemodynamics
n right heart catheter, N-terminal pro–brain natriuretic pep-
ide (NT pro-BNP), quality-of-life scores (Cambridge Pulmo-
ary Hypertension Review, CAMPHOR) and New York Heart
ssociation (NYHA) class. These measurements were re-
eated at trial end (12 weeks) and at 9 months of open-label
tudy (1 year from trial inception). One patient was withdrawn
fter an adverse drug reaction, 1 patient died, 1 patient could
ot tolerate the scanner, and 1 patient had insufficient quality
cans for analysis. The results of this trial have been reported
lsewhere.3 We additionally report longer-term 3-year results
or the therapeutic trial, although this data set is not complete.
RI technique
RI was performed with a 1.5T Sigma CVi system (GE
ealthcare, Milwaukee, WI). Images were acquired using a
hased-array torso coil with respiratory gating and prospective
lectrocardiographic (ECG) gating. Subjects were ECG mon-
tored with a T-wave–suppressing module. Multislice gradient–
igure 1 Time-line of trial protocol. ADR, adverse drug reac-
ion.
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612 The Journal of Heart and Lung Transplantation, Vol 29, No 6, June 2010cho sequences were used to obtain 2-chamber, 4-chamber and
xial volume stacks. All cine sequences with fast imaging
mploying steady-state acquisition (FIESTA) were acquired
ith 25 cardiac phases at 10-mm-thick slices with 128  256
atrices. Interleaved, velocity-encoded, phase-difference se-
uences were used to measure flow and area in the right
ulmonary artery [RAC (%)  ((systolic area  diastolic
rea)/diastolic area)  100]. MRIs were stored on a CCI
icture archive and communication system (PACS) system for
ubsequent recall and analysis. To determine the interobserver
ariability, images were analyzed by 2 study-blind investiga-
ors. Interobserver variability was 10%.
tatistics
o derive significant correlations given the small sample
ize and lack of Gaussian distribution Spearman’s rank
orrelation was used. All data were analyzed using Pear-
on’s correlations and significant correlations only desig-
ated when both methods concurred. The small sample size
recluded multivariate analysis. The Mann–Whitney rank-
um test was used for between-group analysis.
esults
ata regarding baseline demographics, hemodynamics,
MWT and NT pro-BNP are detailed in Table 1. There was
significant correlation between pre-treatment baseline
AC and functional response at 1 year, as determined by
MWT (r  0.70, p  0.006) (Figure 2). RAC at baseline
lso showed a significant correlation for both absolute quan-
itative change and percentage change in NT pro-BNP at 1
ear (r  0.59, p  0.03 and r  0.53, p  0.05, respec-
ively) (Figure 2). This relationship was particularly strong
n the post-PEA residual distal disease group. RAC was
ighly correlated with improvement in 6MWT at 1 year
r  0.91, p  0.002) (Figure 2). In the residual distal
ost-operative disease group RAC also correlated highly
ith absolute and percentage change from baseline in NT
Table 1 Baseline Parameters of CTEPH Subjects
All subjects: baseline
parameters (SD) (n  14)
Age 55.3 (15.0)
Gender (M/F) 3/11
Mean PA pressure (mm Hg) 44.3 (9.6)
Pulmonary vascular resistance
(dynes/s/cm5) 720 (380)
PCWP (mm Hg) 10 (3.6)
Cardiac output (liters/min/m2) 4.2 (1.0)
NT pro-BNP (pg/ml) 1,057 (1,262)
6-minute walk test (m) 336.4 (60.3)
RAC 32.3 (5.6)
CTEPH, chronic thromboembolic pulmonary hypertension; PA, pul
endartectomy; NA, not applicable; NT pro-BNP, N-terminal pro–brain na
aStatistically significant (p  0.05).ro-BNP at 1 year (r  0.90, p  0.005 and r  0.81, p 
.02, respectively) (Figure 2). There was no correlation
etween baseline RAC and change in mean PA pressure
r  0.24, p  0.57), cardiac output (r  0.04, p  0.9)
r change in pulmonary vascular resistance (PVR; r0.14,
 0.74). No other baseline variable correlated with change in
MWT (Table 2) and this was also the case with change in NT
ro-BNP. Only 5 of the subjects were on active drug during the
andomized phase. The correlation between change in 6MWT
nd baseline RAC at 3 months in this group did not reach
tatistical significance (r 0.53, p 0.36). The placebo group
howed no significant correlation at 3 months (r  0.22, p 
.6).
The CAMPHOR quality-of-life score correlated with
AC at 3 months (r  0.78, p  0.001). The comparison of
atients at 1 year who improved by a functional NYHA
lass vs those who did not or deteriorated demonstrated a
igher mean RAC, although this just failed to meet statis-
ical significance (p  0.06) (Figure 3). Of interest, limited
ata were available at 3 years. One of the 17 patients in the
rial died. This patient had an RAC of 19.1%. Of the 11
atients with CAMPHOR scores available at 3 years there
as a continued improvement (mean 4.1, SD 8.4). This
as not just a mean change but a CAMPHOR score im-
rovement in 8 of the 11 subjects. There was therefore some
dditional data to suggest that the improvements in the trial
ere subjectively perceived as being of importance to the
atients and that these improvements continued out to 3
ears. There were limited 6MWT data available at 3 years
or 7 patients. The correlation between the RAC and 6MWT
or the remaining subjects (r 0.42) did not reach statistical
ignificance (p  0.41), but the correlation to NT pro-BNP
emained significant despite the low numbers (r 0.94, p
.016).
Taking into account the small numbers involved, using a
ut-off of PA distensibility of20% across the whole study
opulation, there was an 87.5% sensitivity (95% CI: 45% to
00%) and a 66.7% specificity (95% CI: 22% to 96%) for
mprovement in 6MWT of 40 meters. In the post-opera-
ive distal CTEPH group, again with a cut-off of 20%, this
PEA distal
(SD) (n  8)
Inoperable distal
CTEPH (SD) (n  6)
Post-PEA vs
inoperable (p-value)
(19.1) 54.8 (8.5) 0.69
2/4 NA
(6.9) 51.5 (8.2) 0.012a
(272) 961 (386) 0.036a
(2.9) 10.0 (4.6) 0.86
(0.85) 3.8 (1.2) 0.15
(397) 1,903 (1,550) 0.02a
(79.8) 335 (51.8) 0.86
(7.3) 24 (2.5) 0.34
artery; PCWP, pulmonary capillary wedge pressure; PEA, pulmonary
c peptide; RAC, relative area change.Post-
CTEPH
55.6
1/7
39.1
539
10.1
4.6
389
338.6
22.8
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613Toshner et al. MRI in CTEPHave a sensitivity of 100% (95% CI: 40% to 100%) and
pecificity of 100% (95% CI: 40% to 100%) for improve-
ent in 6MWT over 40 meters. There was no significant
ifference in hemodynamic or functional profile between
hose with a distensibility preserved at 20%, and those at
20% (Table 3).
iscussion
o our knowledge, this is the first trial to look at a distinct
opulation of patients with predominantly distal CTEPH and
he potential importance of the proximal vasculature in re-
ponse to medical treatment. Very recent work has demon-
trated a clear correlation between exercise capacity and MRI
easurement of distensibility.19,20 We have now presented
Table 2 Baseline Variables Correlated With Improvement in 6
Baseline
Age 55.3 (1
Gender M/F 3/11
SpO2 on air (%) 94.6 (2
Systemic mean blood pressure (mm Hg) 98 (1
Mean PA pressure (mm Hg) 44.3 (9
Pulmonary vascular resistance (dynes/s/cm5) 720 (3
PCWP (mm Hg) 10 (3
Cardiac output (liters/min/m2) 4.2 (1
NT pro-BNP (pg/ml) 1,057 (1
RAC 23.3 (5
PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; NT
SpO2, oxygen saturation; 6MWT, 6-minute walk test.
aStatistically significant (p  0.05).ata that suggest this may extend to the response to treatment
ith a significant correlation between PA distensibility, as
easured by RAC at baseline, and functional improvement, as
easured by 6MWT, after 1 year of an RCT and open-label
hase of sildenafil treatment. It is encouraging that the 3-year
ata from this cohort of patients continue to demonstrate that
hese patients seem to have done remarkably well on targeted
reatment despite their poor historic prognosis. This is in line
ith data we have recently presented from the whole UK
opulation.21
The RAC was the only independent baseline variable
emonstrating any relation to the improvement in 6MWT.
n addition, the baseline RAC correlated with the change in
T pro-BNP at 1 and 3 years. As NT pro-BNP has been
hown to reflect right ventricular function,22,23 this relation-
hip is therefore potentially explained by the effect of pre-
Figure 2 Correlations of baseline
PA distensibility, as measured by rela-
tive area change (RAC) of right main
pulmonary artery, with 6MWT im-
provement and NT pro-BNP at 1 year.
PAD correlated with improvement in
6MWT for (A) all subjects and (B)
post-PEA only. PAD correlated with
change in NT pro-BNP for (C) all sub-
jects and (D) post-PEA only. **p 
0.05.
fter 1 Year
eters (SD) Correlation with 6MWT p-value
0.12 0.68
0.17 0.51
0.29 0.31
0.18 0.53
0.16 0.52
0.38 0.18
— 0.15
0.29 0.32
0.43 0.12
0.7 0.006a
P, N-terminal pro–brain natriuretic peptide; RAC, relative area change;MWT A
param
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614 The Journal of Heart and Lung Transplantation, Vol 29, No 6, June 2010erved distensibility on the function of the right ventricle.
aseline RAC did not correlate with change in PVR or
ardiac output measured at rest; however, the most relevant
ardiac output to relate to the 6MWT is on exertion, as this
s a direct contributor to exercise capacity. We did not
erform these measurements.
The current catheter measurements of pulmonary vascu-
ar resistance do not adequately assess right ventricular
fter-load and give no direct information on arterial elas-
ance or compliance.24 Part of the reason these parameters
ave not historically been routinely measured is a lack of
imple methodologic approaches.25 More recently, compli-
nce has been suggested to have a direct inverse relationship
o PVR,26 and PVR coupled with compliance correlated
etter with cardiac index than PVR alone. Capacitance and
istensibility have been demonstrated to correlate with mor-
ality in pulmonary hypertension.16,27 A very recent study
ooking at a mixed group of patients with pulmonary hy-
ertension confirmed that the correlation between PA elas-
icity and exercise capacity was superior to traditional he-
odynamic measurements, but there was no investigation
f treatment response.19 Therefore, parameters measuring
ompliance and after-load have potential roles in the study
nd understanding of disease evolution.
In our study there are 2 potential reasons why RAC
orrelates with response to treatment. The first explanation
igure 3 Comparison of RAC in patients who improved NHYA
lass at 1 year vs those who did did not improve NYHA class.
AC, relative area change (%).
Table 3 Subjects Divided Using 20% RAC Cut-off
Subjects
(n  10)
Age 53.5 (1
Gender (M/F) 3/7
Mean PA pressure (mm Hg) 46.4 (3
Cardiac output (liters/min) 4.27 (0
Pulmonary vascular resistance (dynes/s/cm5) 674.2 (1
6-minute walk test (m) 339.5 (1
PA, pulmonary artery; RAC, relative area change.s that the proximal vasculature is itself a target for the
emodeling properties of sildenafil. PA distensibility would
herefore reflect potential proximal vasodilation. However,
he RAC measurements did not correlate with our original
asodilator studies (data not shown), although the activity
f the whole circuit is perhaps not expected to correlate with
selective proximal measurement. An alternative explana-
ion is that proximal distensibility may reflect downstream
emodeling. The anti-proliferative, anti-remodeling and dis-
al vasodilatory effects of sildenafil could therefore be most
ronounced in subjects with preserved distensibility and,
onsequently, better preserved compliance.
There are notable weaknesses in our study. Our study
opulation was small. This is particularly problematic for
he post-PEA and distal de novo inoperable CTEPH sub-
roups, which were also not well matched for either
unctional level as measured by quality-of-life scores,
MWT, NT pro-BNP and hemodynamic variables.
cross all of these parameters, the inoperable group had
ore severe disease (Table 1). However, both groups had
comparable mean RAC (Table 1), and therefore it is not
imply that the post-operative group had improved he-
odynamics and, as a result, preserved distensibility. It
s likely that the removal of proximal organized thrombus
ormation resulted in altered vessel structure when com-
ared with distal de novo disease. It is a flaw in our study
hat the numbers were too small for accurate statistical
nalysis between these 2 groups; therefore, we avoided
his comparison, despite the post-PEA, in particular,
howing a strong correlation with response to therapy. In
ddition, there is the possibility that in the post-operative
roup there was significantly more proximal disease left
ost-operatively than our imaging studies revealed. The
ubjects were very carefully diagnosed in a multidisci-
linary meeting with up to 4 angiographic imaging mo-
alities and all of our post-PEA patients were considered
o have good technical clearance of accessible proximal
isease, both at operation and on subsequent imaging.
lthough we believe that the categorization is accurate
his remains a potential confounder. Finally, another po-
ential criticism is that the RAC did not correlate with our
riginal vasodilator studies or to pulmonary vascular
esistance. This may be explained by the proximal nature
f the measurement, which will thus give little informa-
ion on the distal vascular resistance or vasoreactivity.
AC 20% Subjects with RAC 20%
(n  4) p-value
58.2 (8.5) 0.74
0/4
39.5 (4.8) 0.24
4.4 (0.47) 0.72
451.0 (137.5) 0.27
331.0 (55.8) 0.84with R
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615Toshner et al. MRI in CTEPHAs a small pilot study the high predictive value of PA
istensibility for improvement in 6MWT and NT pro-BNP
as to be tempered by the large confidence intervals that are
result of the small numbers involved. Validating this will
equire an adequately powered larger study. Regardless, the
emonstration of a non-invasive parameter closely correlat-
ng with therapeutic treatment response, as measured by
mprovement in 6MWT, and right heart function, as mea-
ured by NT pro-BNP, is of clear interest in the future
anagement of CTEPH.
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